Loading...
XSHG600568
Market cap359mUSD
Dec 27, Last price  
1.36CNY
1D
1.49%
1Q
5.43%
Jan 2017
-84.77%
Name

Zhongzhu Healthcare Holding Co Ltd

Chart & Performance

D1W1MN
XSHG:600568 chart
P/E
—
P/S
4.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.30%
Rev. gr., 5y
2.20%
Revenues
639m
+26.21%
451,991,709811,210,4881,481,284,6451,860,169,5842,480,654,1672,021,809,949449,922,594464,148,862627,889,303790,638,3501,069,987,066921,782,3721,098,977,643981,023,762572,861,387696,172,449727,473,784581,059,366505,971,358638,562,819
Net income
-344m
8,756,1580018,435,74340,974,186146,547,84173,765,178183,057,41460,226,00662,430,25832,406,40373,411,041294,174,099169,343,6390014,591,07400-343,935,382
CFO
4m
-86.04%
2,746,85357,267,28448,494,5403,575,32590,740,76300003,556,57614,338,135189,045,815296,576,55000614,570,785248,153,57794,043,01025,524,6773,561,997
Dividend
Aug 07, 20180.02 CNY/sh
Earnings
May 08, 2025

Profile

Zhongzhu Healthcare Holding Co.,Ltd constructs and develops real estate properties in China. It also produces ophthalmic drugs; researches and develops natural botanical drugs. In addition, it researches and develops drugs, such as recombinant human endostatin adenovirus injection, which is an anticancer gene therapy; Genistein capsule for the treatment of postmenopausal osteoporosis; and motherwort that is primarily a gynecological drug. Further, the company offers medical instruments, including radiation therapy, hyperthermia, phototherapy, and ultrasound diagnosis, as well as develops imaging breast tumor detection systems. Additionally, it offers medical services. The company was formerly known as Zhongzhu Holding Co., Ltd. and changed its name to Zhongzhu Healthcare Holding Co.,Ltd in June 2016. Zhongzhu Healthcare Holding Co.,Ltd was founded in 1970 and is headquartered in Qianjiang, China.
URL
http://www.zz600568.com
IPO date
May 18, 2001
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
638,563
26.21%
505,971
-12.92%
581,059
-20.13%
Cost of revenue
797,330
481,192
530,700
Unusual Expense (Income)
NOPBT
(158,767)
24,779
50,360
NOPBT Margin
4.90%
8.67%
Operating Taxes
16
21,059
Tax Rate
41.82%
NOPAT
(158,783)
24,779
29,301
Net income
(343,935)
 
Dividends
(103)
Dividend yield
0.00%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
2,668
14,477
15,096
Long-term debt
25,529
517,077
537,614
Deferred revenue
7,413
9,087
Other long-term liabilities
6,009
419
394
Net debt
(904,287)
(407,773)
(594,238)
Cash flow
Cash from operating activities
3,562
25,525
94,043
CAPEX
(27,259)
Cash from investing activities
(41,217)
Cash from financing activities
(11,491)
FCF
142,726
543,561
(96,275)
Balance
Cash
583,978
612,184
643,588
Long term investments
348,506
327,143
503,359
Excess cash
900,556
914,029
1,117,895
Stockholders' equity
(398,377)
2,248,908
2,241,615
Invested Capital
3,010,281
2,118,071
2,749,871
ROIC
1.02%
1.19%
ROCE
0.80%
1.29%
EV
Common stock shares outstanding
2,023,149
1,992,870
1,992,870
Price
1.72
-8.51%
1.88
-4.08%
1.96
41.01%
Market cap
3,479,817
-7.12%
3,746,595
-4.08%
3,906,025
41.01%
EV
2,711,996
3,477,753
3,442,971
EBITDA
(79,200)
124,374
152,071
EV/EBITDA
27.96
22.64
Interest
7,718
15,000
15,855
Interest/NOPBT
60.53%
31.48%